Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 9/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.51 |
| ▸ | S1PR4 | O95977 | 6/20 | 0.51 |
| ▸ | S1PR5 | Q9H228 | 6/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625282 | 0.99 | FFAR1 (0.52) | FFAR1S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL1628368 | 0.99 | FFAR1 (0.52) | FFAR1S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL3979299 | 0.99 | FFAR1 (0.52) | FFAR1S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL14246856 | 0.91 | FFAR1 (0.52) | FFAR1S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL1626412 | 0.87 | S1PR1 (0.62) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL1626974 | 0.87 | S1PR1 (0.62) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL1624918 | 0.87 | S1PR1 (0.62) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL1626931 | 0.87 | S1PR1 (0.62) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL13844525 | 0.87 | S1PR1 (0.62) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL1626906 | 0.85 | S1PR4 (0.49) | FFAR1S1PR1S1PR3S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753712-B1 | AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2009-05-13 | — | — | EP | claimed |
| US-20070225260-A1 | Amino-Propanol Derivatives | NOVARTIS AG (CH) | 2007-09-27 | — | — | US | claimed |
| EP-1753712-A1 | AMINO-PROPANOL DERIVATIVES | Novartis AG (CH) | 2007-02-21 | — | — | EP | claimed |
| WO-2005118523-A1 | AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2005-12-15 | — | — | WO | claimed |
| US-7928093-B2 | Amino-propanol derivatives | NOVARTIS AG (CH) | 2011-04-19 | — | — | US | disclosed |
| US-7928093-B2 | Amino-propanol derivatives | NOVARTIS AG (CH) | 2011-04-19 | — | — | US | disclosed |
| US-7928093-B2 | Amino-propanol derivatives | NOVARTIS AG (CH) | 2011-04-19 | — | — | US | disclosed |
| EP-1753712-B1 | AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2009-05-13 | — | — | EP | disclosed |
| EP-1753712-B1 | AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2009-05-13 | — | — | EP | disclosed |
| US-20070225260-A1 | Amino-Propanol Derivatives | NOVARTIS AG (CH) | 2007-09-27 | — | — | US | disclosed |
| US-20070225260-A1 | Amino-Propanol Derivatives | NOVARTIS AG (CH) | 2007-09-27 | — | — | US | disclosed |
| US-20070225260-A1 | Amino-Propanol Derivatives | NOVARTIS AG (CH) | 2007-09-27 | — | — | US | disclosed |
| EP-1753712-A1 | AMINO-PROPANOL DERIVATIVES | Novartis AG (CH) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005118523-A1 | AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225260-A1 | Amino-Propanol Derivatives | ADRB1, ADRB3, ARG1 | FFAR1 993/4885S1PR1 1545/4885S1PR3 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.